Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.6174
−$0.5176 · -45.60%
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Previous close
$0.6174
−$0.5176 · -45.60%
After-hours
$0.5949
−$0.0225 · -3.64%
Oct 7, 7:56 PM ET
Regular session · ET · Market data may be delayed.
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Day range
Current $0.6174
52-week range
Current $0.6174
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
42
Fair Value
Sentiment
43
Mixed
Risk
79
High Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Day range
Current $0.6174
52-week range
Current $0.6174
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.16M USD | 9.99M USD | 34.48M USD | 13.85M USD | 9.6M USD |
| Cost of goods sold | 3.65M USD | 3.93M USD | 3.53M USD | 3.64M USD | 984K USD |
| Gross profit | 7.51M USD | 6.07M USD | 30.95M USD | 10.21M USD | 8.61M USD |
| Research and development | 109.44M USD | 130.15M USD | 112.08M USD | 82.23M USD | 52.26M USD |
| Selling, general, and administrative | 37.91M USD | 46.46M USD | 38.46M USD | 38.02M USD | 23.34M USD |
| Operating expenses | 143.71M USD | 172.68M USD | 147.01M USD | 116.61M USD | 75.59M USD |
| Interest income | 8M USD | — | 10.7M USD | 4.6M USD | 148K USD |
| Interest expense | — | — | — | — | 8K USD |
| Depreciation and amortization | 3.65M USD | 3.93M USD | 3.53M USD | 1.62M USD | 984K USD |
| Operating income | −136.19M USD | −166.62M USD | −116.06M USD | −106.4M USD | −66.98M USD |
| Net income | −148.13M USD | −149.11M USD | −102.07M USD | −99.42M USD | −66.92M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$1.00
61.97% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.64M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM2.64M0.00%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF1.62M0.00%95.4B USD0.05%$233.49-1.56%
Vanguard Russell 2000 ETFVTWO813.1K0.00%18B USD0.06%$112.21-1.26%
iShares Biotechnology ETFIBB764.24K0.01%10.4B USD0.44%$203.34+0.12%
Schwab U.S. Small-Cap ETFSCHA639.22K0.00%22.01B USD0.03%$32.61-1.47%
Dimensional - US Small Cap ETFDFAS422.12K0.00%34.14B USD0.31%$77.92-1.38%
Fidelity Enhanced Small Cap ETFFESM382.23K0.01%6.41B USD0.28%$45.22-1.14%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
